ISR [Bioanalytics]

posted by Dr_Dan  – Germany, 2012-11-29 17:30 (4563 d 15:48 ago) – Posting: # 9638
Views: 9,460

Dear all
The EGA (European Generic Association) sent a letter to the CMDh asking for a clarified joint statement by the EMA PKWP and the CMDh regarding the retrospective application of the bioanalytical method validation guideline for all studies performed (and completed) before finalisation of the guideline and already part of approved dossiers. As a reply CMDh is saying ‘indeed, it is under discussion’. In other words, they do not want to involve anybody in the discussion at this stage.
However, once you received a marketing authorisation for a product you will not have to withdraw the product if your study submitted with the dossier is not compliant with the current guideline. In my opinion if you run a repeat use procedure your original MA should not be in danger of being revoked. Otherwise in this sense all marketing authorisation for generic products would be affected by the new guideline on method validation and this can not be. As stated by the CMDh this is only applicable for applications submitted after February this year.
I hope this helps.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
58 visitors (0 registered, 58 guests [including 15 identified bots]).
Forum time: 10:18 CEST (Europe/Vienna)

It’s difficult to work in a group
when you are omnipotent.    John de Lancie (as Q)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5